Helsinn Group has renewed a distribution and licence agreement with Angelini Pharma for the commercialisation of AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries.
Lugano (Switzerland) and Rome (Italy)– May 27, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an international pharmaceutical company, part of the Italian privately-owned multi-business Angelini Industries, that researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health, announce today the signing of the Distribution and Licence Agreement renewal in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN® and MESULID® (Nimesulide) for the treatment of acute (short-term) pain.
Angelini Pharma has revealed that cenobamate has been reimbursed for adjunctive treatment of focal onset seizures with or without secondary generalisation among adult patients with epilepsy.
ROME, May 11 (Reuters) - Family-owned Italian industrial conglomerate Angelini is set to invest up to $505.5 million to fund development of a new treatment for epilepsy by Japan's JCR Pharmaceuticals (4552.T), capable of penetrating the blood-brain barrier.
PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Industries, has launched cenobamate in France.
Cenobamate (ONTOZRY®), for the Treatment of Uncontrolled Focal-onset Seizures in Adults, Is Now Available in France and Belgium
Angelini Industries appoints Jacopo Andreose new CEO of Angelini Pharma
PARIS--(BUSINESS WIRE)--Angelini Pharma, international pharmaceutical company part of the privately held Italian Angelini Group announced today that ONTOZRY® (cenobamate) is now available in the Netherlands for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults patients who have not been adequately controlled despite an history of treatment with at least two anti-epileptic medicinal products. The product obtained approval from The European Medicines Agency in March’21.
PARIS--(BUSINESS WIRE)--On the occasion of Purple Day (March 26, 2022), an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy.
PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy.